# GHK-Cu Hair Loss: What the Research Shows on Follicle Stimulation and Growth > GHK-Cu hair loss research spans follicle stimulation in C3H mice (1991), a 6-month RCT in 45 androgenetic alopecia patients (2016), and VEGF upregulation in dermal fibroblasts. Full literature digest. From the 1991 C3H mouse follicle study to the 2016 RCT and the 2026 hair-peptide review — the GHK-Cu hair loss literature plated plainly. ## The strongest clinical evidence: Lee et al. 2016 RCT GHK-Cu hair loss research has one controlled human trial as its strongest anchor. Lee et al. (2016, PMID 27489425) conducted a randomized double-blind 6-month study in 45 men with androgenetic alopecia (Norwood-Hamilton types II–V). Two treatment groups received daily topical scalp spray combining 5-aminolevulinic acid (5-ALA) with GHK (ALAVAX at 50 or 100 mg/ml). At 6 months: - Group A (50 mg/ml): 52.6 additional hairs per unit area versus 9.6 in the placebo group. - Group B (100 mg/ml): 71.5 additional hairs per unit area — a ratio of change of 2.38 versus 1.21 in placebo. - No adverse events were reported in either treatment group [11]. This is the primary human controlled trial for GHK-Cu in hair growth. Important caveats: the active treatment combined GHK with 5-ALA; the independent contribution of GHK alone cannot be isolated from this study design. The sample size of 45 is small. No 12-month follow-up data have been published. Does GHK-Cu help with hair loss? In vitro studies have shown GHK-Cu stimulates hair follicle cell proliferation and upregulates hair-specific keratin genes. This 6-month scalp spray RCT is the strongest human evidence, showing statistically significant hair count increases with no adverse events [11]. ## Preclinical and in vitro evidence for GHK-Cu hair growth The hair follicle-stimulating properties of GHK-Cu were first characterized in inbred C3H mice at ProCyte Corporation. Trachy et al. (1991) demonstrated stimulation of hair follicle cycling and growth in the C3H inbred mouse model using peptide copper complex PC 1038 [21]. This was the foundational preclinical evidence that initiated subsequent dermatological research. Does copper peptide work for hair growth? Copper peptides including GHK-Cu have been studied in vitro for hair follicle stimulation since 1991. Some in vivo scalp models suggest thickening effects, but no large placebo-controlled human trials for GHK-Cu alone have been published as of 2026. A 2026 Biomedicines review of short peptides for hair loss confirmed that GHK-Cu upregulates VEGF in dermal fibroblasts and promotes extracellular matrix turnover via MMP activation. Phase I clinical evidence for hair growth promotion in 45 AGA patients is summarized in the review [22]. The review also notes GHK-Cu's use as a component of the QR678 Neo storage solution for transplanted hair grafts — a practical clinical application that establishes its safety profile in direct follicle contact. ## Proposed mechanisms for GHK-Cu hair follicle effects Several mechanisms have been proposed for GHK-Cu's effects on hair follicles, drawing from its broader biology: **VEGF upregulation.** GHK-Cu upregulates vascular endothelial growth factor in dermal fibroblasts [22]. Hair follicles are highly vascularized structures; improved vascularization of the dermal papilla is a recognized pathway for follicle anabolic activity. **Extracellular matrix remodeling.** GHK-Cu promotes ECM turnover via MMP activation [22] and stimulates collagen I and III synthesis in dermal fibroblasts [1, 2]. The dermal papilla is embedded in ECM; matrix remodeling supports follicle cycling. **Keratinocyte proliferative potential.** Copper-GHK at 0.1–10 micromolar increased integrin expression and p63 positivity in basal keratinocytes [12] — indicators of enhanced stemness and proliferative potential in the interfollicular epidermis. What timelines have been observed in GHK-Cu skin research? The Lee 2016 RCT demonstrated statistically significant hair count increases at 6 months of continuous topical use. No shorter-duration hair growth data have been published in controlled trial format. GHK-Cu vs. retinol: different mechanisms in anti-aging research. For hair specifically, retinol is not a studied comparator for GHK-Cu in published trials. Retinol acts via RAR/RXR pathways; GHK-Cu via copper-dependent and VEGF-mediated mechanisms — non-overlapping pathways [7]. ## Gaps in the GHK-Cu hair research record The hair loss literature for GHK-Cu has a specific profile: one strong human RCT [11], one older preclinical mouse study [21], a 2026 review confirming the mechanism [22], and no large-scale independent replication. Key research gaps: - No published RCT isolating GHK-Cu alone (the Lee 2016 trial combined it with 5-ALA). - No published comparison against established androgenetic alopecia treatments (finasteride, minoxidil) in any controlled format. - No published data for GHK-Cu in female pattern hair loss. - No dose-response data for topical GHK-Cu concentration in hair growth. - No data for injectable GHK-Cu in any hair model. For [GHK-Cu side effects and safety](/dosage#side-effects) including the theoretical copper accumulation concern, see the dosage page. For the full research record see the [GHK-Cu mechanism of action](/research#mechanism). --- Hand-set from the peer-reviewed record like a family recipe — each study plated on this table, sourced to its paper, prescribed by no clinic.